Joinn Laboratories Opts for Instem's Preclinical Software Suite [Professional Services Close - Up]
(Professional Services Close - Up Via Acquire Media NewsEdge) Instem, a provider of IT solutions, announced that Joinn Laboratories, a provider of preclinical services, has purchased the Provantis preclinical solution suite.
In a release, the Company noted that Joinn provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services with a heightened focus on quality.
Yuxia Feng, President and CEO Joinn, said "We were looking for a market leading solution to support our long term growth plans and we are confident that our investment in Provantis will help to deliver demonstrable efficiency improvements within our R&D facilities. We are looking forward to a long and successful partnership with Instem."
Phil Reason, President and CEO Instem, said, "We are delighted to welcome Joinn to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the long term growth potential in what is already the third largest pharmaceutical market in the world."
Joinn's R&D operations are located in Beijing and Suzhou (Taicang Biomedical Industrial Park).
((Comments on this story may be sent to firstname.lastname@example.org))
(c) 2013 ProQuest Information and Learning Company; All Rights Reserved.
[ Back To Technology News's Homepage ]